Wells Fargo’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $264K | Sell |
58,709
-108,312
| -65% | -$474K | ﹤0.01% | 4533 |
|
|
2025
Q4 | $803K | Buy |
167,021
+71,570
| +75% | +$322K | ﹤0.01% | 4130 |
|
|
2025
Q3 | $433K | Buy |
95,451
+14,983
| +19% | +$55K | ﹤0.01% | 4403 |
|
|
2025
Q2 | $249K | Buy |
80,468
+8,303
| +12% | +$27.6K | ﹤0.01% | 4641 |
|
|
2025
Q1 | $252K | Buy |
72,165
+1,566
| +2% | +$5.22K | ﹤0.01% | 4536 |
|
|
2024
Q4 | $231K | Buy |
70,599
+21,768
| +45% | +$80.1K | ﹤0.01% | 4708 |
|
|
2024
Q3 | $188K | Buy |
48,831
+694
| +1% | +$2.66K | ﹤0.01% | 4624 |
|
|
2024
Q2 | $149K | Buy |
48,137
+5,247
| +12% | +$15.7K | ﹤0.01% | 4699 |
|
|
2024
Q1 | $111K | Buy |
42,890
+5,324
| +14% | +$13.8K | ﹤0.01% | 4831 |
|
|
2023
Q4 | $93.9K | Buy |
37,566
+5,458
| +17% | +$10.7K | ﹤0.01% | 4941 |
|
|
2023
Q3 | $65.2K | Sell |
32,108
-23,129
| -42% | -$48.5K | ﹤0.01% | 5036 |
|
|
2023
Q2 | $127K | Buy |
55,237
+27,381
| +98% | +$71.3K | ﹤0.01% | 4885 |
|
|
2023
Q1 | $84.4K | Buy |
27,856
+18,755
| +206% | +$52.9K | ﹤0.01% | 4893 |
|
|
2022
Q4 | $21.2K | Buy |
9,101
+1,179
| +15% | +$2.82K | ﹤0.01% | 5234 |
|
|
2022
Q3 | $14K | Buy |
7,922
+301
| +4% | +$709 | ﹤0.01% | 5539 |
|
|
2022
Q2 | $20K | Sell |
7,621
-87,185
| -92% | -$223K | ﹤0.01% | 5436 |
|
|
2022
Q1 | $282K | Sell |
94,806
-22,885
| -19% | -$70.1K | ﹤0.01% | 4781 |
|
|
2021
Q4 | $458K | Sell |
117,691
-306,731
| -72% | -$1.19M | ﹤0.01% | 4729 |
|
|
2021
Q3 | $1.82M | Buy |
424,422
+420,496
| +10,711% | +$1.4M | ﹤0.01% | 3747 |
|
|
2021
Q2 | $12K | Sell |
3,926
-750
| -16% | -$2.32K | ﹤0.01% | 6072 |
|
|
2021
Q1 | $15K | Sell |
4,676
-36
| -0.8% | -$139 | ﹤0.01% | 6223 |
|
|
2020
Q4 | $17K | Sell |
4,712
-624
| -12% | -$2.19K | ﹤0.01% | 5892 |
|
|
2020
Q3 | $16K | Buy |
5,336
+2,436
| +84% | +$7.41K | ﹤0.01% | 5800 |
|
|
2020
Q2 | $5K | Hold |
2,900
| – | – | ﹤0.01% | 5962 |
|
|
2020
Q1 | $3K | Sell |
2,900
-100
| -3% | -$270 | ﹤0.01% | 5919 |
|
|
2019
Q4 | $8K | Hold |
3,000
| – | – | ﹤0.01% | 5936 |
|
|
2019
Q3 | $5K | Sell |
3,000
-2,014
| -40% | -$3.47K | ﹤0.01% | 6047 |
|
|
2019
Q2 | $10K | Sell |
5,014
-48,924
| -91% | -$125K | ﹤0.01% | 5915 |
|
|
2019
Q1 | $193K | Buy |
53,938
+12,001
| +29% | +$46.1K | ﹤0.01% | 4842 |
|
|
2018
Q4 | $161K | Sell |
41,937
-26,126
| -38% | -$129K | ﹤0.01% | 5055 |
|
|
2018
Q3 | $644K | Buy |
68,063
+21,737
| +47% | +$216K | ﹤0.01% | 4267 |
|
|
2018
Q2 | $339K | Buy |
46,326
+43,325
| +1,444% | +$258K | ﹤0.01% | 4721 |
|
|
2018
Q1 | $15K | Sell |
3,001
-400
| -12% | -$2.12K | ﹤0.01% | 5865 |
|
|
2017
Q4 | $17K | Buy |
3,401
+1
| +0% | +$6 | ﹤0.01% | 5820 |
|
|
2017
Q3 | $21K | Sell |
3,400
-295
| -8% | -$1.26K | ﹤0.01% | 5696 |
|
|
2017
Q2 | $13K | Buy |
3,695
+170
| +5% | +$585 | ﹤0.01% | 5718 |
|
|
2017
Q1 | $11K | Buy |
3,525
+330
| +10% | +$916 | ﹤0.01% | 5844 |
|
|
2016
Q4 | $8K | Buy |
3,195
+200
| +7% | +$582 | ﹤0.01% | 5852 |
|
|
2016
Q3 | $10K | Hold |
2,995
| – | – | ﹤0.01% | 5753 |
|
|
2016
Q2 | $10K | Hold |
2,995
| – | – | ﹤0.01% | 5660 |
|
|
2016
Q1 | $12K | Buy |
2,995
+25
| +0.8% | +$89 | ﹤0.01% | 5633 |
|
|
2015
Q4 | $13K | Buy |
2,970
+170
| +6% | +$932 | ﹤0.01% | 5672 |
|
|
2015
Q3 | $17K | Sell |
2,800
-260
| -8% | -$2.31K | ﹤0.01% | 5583 |
|
|
2015
Q2 | $36K | Buy |
3,060
+300
| +11% | +$4.57K | ﹤0.01% | 5423 |
|
|
2015
Q1 | $48K | Buy |
2,760
+2,300
| +500% | +$47.1K | ﹤0.01% | 5023 |
|
|
2014
Q4 | $7K | Buy |
460
+60
| +15% | +$1.04K | ﹤0.01% | 5750 |
|
|
2014
Q3 | $8K | Sell |
400
-784,738
| -100% | -$12.8M | ﹤0.01% | 5665 |
|
|
2014
Q2 | $10.3M | Sell |
785,138
-4,545
| -0.6% | -$64.4K | ﹤0.01% | 1803 |
|
|
2014
Q1 | $17M | Buy |
+789,683
| New | +$14.2M | 0.01% | 1378 |
|
|
2013
Q4 | – | Sell |
-200
| Closed | -$1K | – | 5703 |
|
|
2013
Q3 | $1K | Hold |
200
| – | – | ﹤0.01% | 5504 |
|
|
2013
Q2 | $1K | Buy |
+200
| New | +$947 | ﹤0.01% | 5443 |
|
Other funds holding ABUS
TSC
WCM
VCM
RCMNY
ACM
Wells Fargo's ABUS Position: Q1 2026 in Review
Wells Fargo reduced its Arbutus Biopharma (ABUS) stake by 65% in Q1 2026, selling an estimated $474K and leaving 58,709 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #4533.
Wells Fargo first reported a position in ABUS in Q2 2013 and has held it in 51 quarters since. The position peaked at $17M in Q1 2014. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.
- Wells Fargo held 58,709 shares of Arbutus Biopharma worth $264K as of Q1 2026.
- Wells Fargo sold 108,312 Arbutus Biopharma shares in Q1 2026, an estimated $474K.
- Arbutus Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4533 holding.
- Wells Fargo first reported a position in Arbutus Biopharma in Q2 2013 and has held it in 51 quarters since.
- Wells Fargo's Arbutus Biopharma position peaked at $17M in Q1 2014.
- 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.